RxDoctor Payments Data

Rebecca Alexander, APRN

Family · Brentwood, TNNPI 1063948602

Payments from drug & device makers

$2,696in general payments, 2019–2025

Across 72 payments — averaging $37.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Respicardia, Inc.$1K
  • AstraZeneca$456
  • Novartis$355
  • Pfizer$238
  • Johnson & Johnson$66
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$64
  • plus $289 from 10 others

What the payments were for

  • Travel & lodging$1,22746%
  • Food & beverage$1,46954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,696 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$24,508
Medicare patients
180
Services billed
308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban427$383,011
EntrestoSacubitril/Valsartan140$133,240
XareltoRivaroxaban99$86,227
FarxigaDapagliflozin Propanediol95$68,889
BrilintaTicagrelor27$26,646
CorlanorIvabradine Hcl18$10,246
VascepaIcosapent Ethyl22$9,521
Amiodarone Hcl174$7,579
Metoprolol Succinate410$4,176
Atorvastatin Calcium373$3,035
Ranolazine ErRanolazine42$2,580
Flecainide Acetate67$1,763
Carvedilol219$1,363
ClopidogrelClopidogrel Bisulfate203$1,349
Isosorbide Mononitrate ErIsosorbide Mononitrate165$1,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$238$383,011427 claims
NovartisEntresto$355$133,240140 claims
AstraZenecaFarxiga, Brilinta$456$95,535122 claims
Johnson & JohnsonXarelto$66$86,22799 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Brentwood

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →